NCT06274294View on ClinicalTrials.gov

Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC

PHASE3RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

CT-P13

Induction treatment.

Trial Locations (1)

92200

RECRUITING

Institut des MICI, Neuilly-sur-Seine

All Listed Sponsors

collaborator

Paris IBD Center

OTHER

collaborator

Celltrion HealthCare France

INDUSTRY

lead

CMC Ambroise Paré

OTHER

NCT06274294 - Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC | Biotech Hunter | Biotech Hunter